Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06395389
Other study ID # Pro00133931
Secondary ID K12DA031794
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 2024
Est. completion date June 2025

Study information

Verified date May 2024
Source Medical University of South Carolina
Contact Kathryn Gex, Ph.D.
Phone (843) 792-4904
Email soltisk@musc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare two brief interventions targeting potentially problematic cannabis use in emerging adults (ages 18-25). Brief interventions are two 40-50 minute sessions separated by 1 week. Eligible emerging adults will complete a detailed cannabis assessment (biological and self-report), followed by one of the two brief interventions, and three follow-up assessments: one immediately after the second session and at 1- and 3-months post-intervention. Assignment to the brief intervention is random. Salivary samples will be collected at baseline, post-intervention, and both follow-ups, for a total of 4 samples, to be tested for tetrahydrocannabinol (THC) and cannabidiol (CBD).


Description:

Cannabis is the most widely used federally illicit substance among emerging adults (age 18-25) in the U.S., and frequent cannabis use is associated with myriad long-term health, social, and academic/occupational consequences. Despite this, rates of perceived risk of daily/regular cannabis use have steadily declined over the past two decades, and this is associated with increased frequency of use, a risk for for Cannabis Use Disorder (CUD). Brief interventions (BIs) are among the most frequently used approaches for addressing problematic or potentially problematic substance use in non-treatment-seeking adolescents and young adults. Although several cannabis brief interventions have been developed and tested to date, meta-analyses indicate that the efficacy of these interventions for emerging adults is mixed and the quality of studies is low, suggesting that novel approaches and rigorous methodology are necessary to improve efficacy. The current study will evaluate the feasibility, acceptability, and preliminary efficacy of a novel cannabis BI for emerging adults who frequently use cannabis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date June 2025
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 25 Years
Eligibility Inclusion Criteria: - Ages 18-25 - Self-Report report cannabis use on at least 20 days of the past 30 days. - Completion of an Intake Visit (PRO #94743) in the past 30 days - Submit a positive urine cannabinoid test during the Intake Visit Exclusion Criteria: - Currently engaged in substance use treatment for any type of substance use - Severe alcohol use disorder or presence of any substance use disorder (SUD) requiring a higher level of care - Significant or acutely unstable medical or psychiatric problems (i.e., psychosis, mania) that would contraindicate research procedures, interfere with safety, compromise data integrity, or preclude consistent study participation - Significant risk of suicide or homicide

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Health Education (HealthEdu)
The Health Education condition is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session focuses on providing in-depth information on good sleep hygiene and habits to improve sleep and information on positive eating habits, nutrition, and physical activity/functional exercise. The second session focuses on providing information about good financial health and related life skills.
Values in Action (VIA)
VIA is a 2-session brief intervention with each session lasting 40-50 minutes and separated by about 1 week (5-10 days). The first session encourages participants to ask themselves what is important to them. This discussion emphasizes identifying values and ways to live in line with their values, as well as why they use cannabis and providing personalized feedback related to their reasons for use. The second session asks participants to reflect on information from session one and consider what they would like to do next to live in line with their values.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Medical University of South Carolina National Institute on Drug Abuse (NIDA)

Outcome

Type Measure Description Time frame Safety issue
Other Comprehensive Marijuana Motives Questionnaire (CMMQ) This is a 44-item measure capturing the various reasons why the individual uses cannabis, including for enjoyment/enhancement, coping, social anxiety, sleep, celebration, boredom, conformity, expansion, and others. For each item, participants select 1 (almost never/never), 2 (some of the time), 3 (half the time), 4 (most of the time), or 5 (almost always/always). Higher average scores indicate more reasons for cannabis use / using cannabis more often for identified reasons. Baseline, 1-month follow-up, 3-month follow-up
Other Protective Behavioral Strategies - Marijuana (PBSM) This is a 36-item measure that assesses the use of different cognitive and behavioral strategies that are intended to minimize harms or negative consequences associated with cannabis use. For each item, participants select 1 (Never), 2 (Rarely), 3 (Occasionally), 4 (Sometimes), 5 (Usually), or 6 (Always). Higher scores indicate more frequent use of strategies to reduce the risk of harm or negative consequences from cannabis use. Baseline, 1-month follow-up, 3-month follow-up
Other Consideration of Future Consequences Scale (CFCS) This is a 12-item scale that assesses how characteristic or uncharacteristic it is for the individual to take into account the future consequences of an action or choice made in the present moment. Participants rate each item from 1 to 5: 1 (extremely uncharacteristic), 2 (somewhat uncharacteristic), 3 (uncertain), 4 (somewhat characteristic), 5 (extremely characteristic). Higher scores indicate a greater consideration of future consequences. Baseline, 1-month follow-up, 3-month follow-up
Other The Adolescent Reinforcement Survey Schedule - Substance Use Version (ARSS-SUV) This is a 35-item assessment of day-to-day activities that individuals engage in with or without the use of substances (in this case cannabis) and the extent to which they enjoyed participating in the activity with or without substance use. For each frequency item, participants select 0 (not engaged), 1 (once a week or less), 2 (2-4 times per week), 3 (about once a day), or 4 (more than once a day). For each enjoyment item, participants select (0 (unpleasant/neutral), 1 (mildly pleasant), 2 (moderately pleasant), 3 (very pleasant), or 4 (extremely pleasant). A cross-product of frequency and enjoyment is created for each item to calculate final scores of substance-free reinforcement and substance-related reinforcement. A reinforcement ratio is then calculated for substance-free and substance-related activities by dividing each score from the sum of both scores (i.e., substance-free / (substance-free + substance-related); or substance-related / (substance-free + substance-related)). Baseline, 1-month follow-up, 3-month follow-up
Primary Timeline Followback (TLFB) The TLFB is a calendar based assessment that is able to capture the frequency and quantity of substance use and other measurable behaviors. Responders identify anchor dates to facilitate recall of days in which substances were used. Baseline, 1-month follow-up, 3-month follow-up
Secondary Marijuana Assessment of Problems Inventory (MAPI) This is a 23-item assessment of the frequency in which problems or negative consequences associated with cannabis use have occurred. For each item, participants select 0 times, 1-2 times, 3-5 times, 6-10 times, or 10+ times in the past month. Higher scores on this inventory indicate a higher frequency of problems or consequences experienced. Baseline, 1-month follow-up, 3-month follow-up
Secondary Mini International Neuropsychiatric Interview (MINI) Cannabis Use Disorder Module This is a 12-item semi-structured clinician interview that assesses diagnostic symptom criteria of cannabis use disorder (CUD) from the Diagnostic and Statistical Manual 5th Edition (DSM-5). Clinicians select either 'yes' or 'no' for the presence of the symptom. Baseline, 1-month follow-up, 3-month follow-up
Secondary Oral Fluid Biospecimen Assay This is a relatively brief objective assessment of recent cannabis use that is collected through mouth swab and is tested at Forensic Fluids Laboratory for the presence of delta-9 tetrahydrocannabinol (THC), delta-8 THC, and cannabidiol (CBD) using a cut-off of 1 nanogram/liter. Baseline, 2-week follow-up, 1-month follow-up, 3-month follow-up
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05726617 - Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders N/A
Not yet recruiting NCT04139668 - Vivitrol Treatment for Cannabis Use Disorder Phase 2
Completed NCT01656707 - Adaptive Treatment for Adolescent Cannabis Use Disorders N/A
Completed NCT03204305 - Brain Imaging of Cannabinoid Receptors Early Phase 1
Completed NCT05005013 - A Teleheath tDCS Approach to Decrease Cannabis Use N/A
Recruiting NCT05292547 - Repetitive Transcranial Magnetic Stimulation to People With Cannabis Use Disorder (SToP-C-rTMS x CUD) N/A
Completed NCT02932215 - Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder Phase 1
Completed NCT03430050 - Progesterone for Cannabis Withdrawal Early Phase 1
Withdrawn NCT03629106 - Effects of Cannabis Abstinence on Symptomology and Cognition in Bipolar Disorder N/A
Completed NCT03334721 - Gabapentin for Bipolar & Cannabis Use Disorders Phase 2
Recruiting NCT04721353 - Reducing Cannabis Overuse With Prazosin Phase 4
Completed NCT03718520 - The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
Completed NCT03624933 - Effects of Cannabis Abstinence on Symptoms and Cognition in Depression N/A
Recruiting NCT05836207 - Rewards for Cannabis Abstinence-study N/A
Not yet recruiting NCT06114212 - Deep Repetitive Transcranial Magnetic Stimulation for Cannabis Use Disorder N/A
Recruiting NCT05855668 - Phenotyping Patients With Alcohol and Cannabis Use Disorders Using the Addictions Neuroclinical Assessment N/A
Recruiting NCT04517474 - Comparing the Spanish Version of CANreduce With or Without Psychological Support and Treatment as Usual, Reducing Cannabis Use. N/A
Recruiting NCT05885542 - SCORE Emerging Adult Cannabis Use & Stress Phase 1/Phase 2
Not yet recruiting NCT06085222 - Evaluation of a Brief Computerized and Smart Phone-based Intervention for Stress in Regular Cannabis Users Phase 1
Completed NCT03056482 - Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC) Phase 4